Vergote I - Search Results

1

Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.

Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A. Keldsen N, et al. Among authors: vergote i. Gynecol Oncol. 2003 Feb;88(2):118-22. doi: 10.1016/s0090-8258(02)00103-8. Gynecol Oncol. 2003. PMID: 12586589 Clinical Trial.

2

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.

D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I. D'Agostino G, et al. Among authors: vergote i. Gynecol Oncol. 2003 Mar;88(3):266-9. doi: 10.1016/s0090-8258(03)00011-8. Gynecol Oncol. 2003. PMID: 12648573 Clinical Trial.

3

Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis.

Amant F, Vloeberghs V, Woestenborghs H, Moerman P, Vergote I. Amant F, et al. Among authors: vergote i. Gynecol Oncol. 2003 Aug;90(2):372-7. doi: 10.1016/s0090-8258(03)00326-3. Gynecol Oncol. 2003. PMID: 12893202

4

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J. Rustin GJ, et al. Among authors: vergote i. J Natl Cancer Inst. 2004 Mar 17;96(6):487-8. doi: 10.1093/jnci/djh081. J Natl Cancer Inst. 2004. PMID: 15026475 No abstract available.

5

Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer.

Cadron I, Jakobsen A, Vergote I. Cadron I, et al. Among authors: vergote i. Gynecol Obstet Invest. 2005;59(3):126-9. doi: 10.1159/000082750. Epub 2004 Dec 14. Gynecol Obstet Invest. 2005. PMID: 15604591 Clinical Trial.

6

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.

Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L. Hirte H, et al. Among authors: vergote ib. Gynecol Oncol. 2006 Aug;102(2):300-8. doi: 10.1016/j.ygyno.2005.12.020. Epub 2006 Jan 25. Gynecol Oncol. 2006. PMID: 16442153 Clinical Trial.

7

Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer.

Vergote I, Amant F. Vergote I, et al. Gynecol Oncol. 2006 Sep;102(3):415-7. doi: 10.1016/j.ygyno.2006.08.001. Gynecol Oncol. 2006. PMID: 16979430 No abstract available.

8

Ovarian cancer.

Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I. Colombo N, et al. Among authors: vergote i. Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79. doi: 10.1016/j.critrevonc.2006.03.004. Epub 2006 Oct 2. Crit Rev Oncol Hematol. 2006. PMID: 17018256 Review.

9

A new prognostic model for FIGO stage 1 epithelial ovarian cancer.

Obermair A, Fuller A, Lopez-Varela E, van Gorp T, Vergote I, Eaton L, Fowler J, Quinn M, Hammond I, Marsden D, Proietto A, Carter J, Davy M, Tripcony L, Abu-Rustum N. Obermair A, et al. Among authors: vergote i. Gynecol Oncol. 2007 Mar;104(3):607-11. doi: 10.1016/j.ygyno.2006.09.021. Epub 2006 Nov 7. Gynecol Oncol. 2007. PMID: 17092548

10

The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.

Cadron I, Leunen K, Amant F, Van Gorp T, Neven P, Vergote I. Cadron I, et al. Among authors: vergote i. Gynecol Oncol. 2007 Aug;106(2):354-61. doi: 10.1016/j.ygyno.2007.04.003. Epub 2007 May 11. Gynecol Oncol. 2007. PMID: 17499348

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

888 results

Search Page

Filters